Image Source: healthdigital.com

France has traditionally treated ageing primarily as a challenge for healthcare and pensions. Investor Nicole Junkermann is among those betting that will change — its latest demographic projections suggest that healthy longevity is increasingly becoming an innovation and investment question as well.

In June, Insee projected that the number of people aged 65 or over in France could rise from 15.3 million in 2026 to 21.1 million by 2070. Their share of the population would increase from 22 per cent to 32 per cent, while the number aged 80 or over could more than double from 4.3 million to almost 9 million.

Those figures help explain why longevity is moving into mainstream life sciences. Nicole Junkermann, founder of NJF Holdings, is among the investors treating healthy ageing as part of a broader biomedical opportunity rather than a speculative pursuit of extreme lifespans.

The investment case is about healthspan

Through NJF Capital, the venture investment arm of NJF Holdings, Nicole Junkermann has backed companies working across biotechnology, artificial intelligence and medical research. One of them is Cambrian Biopharma, which develops therapeutic programmes targeting biological mechanisms associated with ageing.

In February 2026, Cambrian announced an award of up to $30.8 million from the US Advanced Research Projects Agency for Health (ARPA-H). The funding supports development of selective mTORC1 inhibitors intended to improve intrinsic capacity in older people, placing measurable health outcomes rather than abstract life extension at the centre of the programme.

This illustrates where the more credible longevity industry is heading. The field is gradually moving away from sweeping promises about reversing ageing and towards specific biological pathways that can be investigated through conventional scientific and clinical processes.

The relevant concept is healthspan rather than lifespan. Living longer produces very different economic consequences depending on whether those additional years are spent independently and in good health or managing chronic disease and disability.

Insee’s projections make that distinction particularly important for France because most of the increase in the older population will come from those aged 80 and above. The country could have almost 9 million people in that age group by 2070.

The AI Connection Nicole Junkermann Keeps Coming Back To

The longevity economy extends well beyond businesses explicitly described as anti-ageing companies. It includes diagnostics, metabolic health, oncology, precision medicine and artificial intelligence-enabled drug discovery.

Nicole Junkermann’s wider portfolio through NJF Holdings reflects several parts of that ecosystem. NJF Capital has backed Owkin, the Paris-founded AI company working with biomedical and clinical information, as well as Deep Genomics and Cambrian Biopharma.

Owkin isn’t itself a longevity company, which helps illustrate the point. Technologies likely to improve healthy ageing may emerge through better cancer treatment, earlier diagnosis or more effective drug discovery rather than through products marketed specifically around longevity.

Artificial intelligence can potentially improve scientists’ ability to understand the complex biological processes underlying many of those conditions. Biotechnology then provides ways of turning that understanding into interventions that can be tested clinically.

Nicole Junkermann has connected these themes with the broader investment philosophy she describes as the Human Code. The idea places human outcomes at the centre of technological progress, making healthy ageing one of its more concrete applications. Readers who want to read more from Nicole Junkermann on these themes can do so there.

An additional decade of life has one kind of value, while an additional decade in which someone remains mobile, independent and socially active has considerably more. That distinction has economic consequences for healthcare systems, families and labour markets as well as for individuals.

Private investment can’t solve France’s demographic challenge, and medicine can’t prevent ageing itself. But capital can help accelerate companies developing ways to reduce the burden of diseases associated with ageing.

For Nicole Junkermann and NJF Holdings, that makes longevity less a speculative bet on extraordinary lifespans and more a long-term investment in human health. France’s demographic numbers suggest the market for those technologies is likely to become considerably larger.